SYTL5

Across TCGA pan-cancer cohorts, SYTL5 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SYTL5’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SYTL5 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types SYTL5 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where SYTL5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SYTL5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	All	−0.759	.017	6	view →
LUAD	All	All	−0.314	.003	5	view →
LSCC	Male	All	−0.680	.003	2	view →
PDAC	Female	III,IV	+2.333	.003	1	view →
CCRCC	All	All	+0.371	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SYTL5–HNSC

Open the HNSC breakdown →